Cargando…

M1 macrophage predicted efficacy of neoadjuvant camrelizumab combined with chemotherapy vs chemotherapy alone for locally advanced ESCC: A pilot study

INTRODUCTION: The efficacy and safety of immunotherapy have been widely recognized in gastrointestinal-related cancers. However, the efficacy of neoadjuvant camrelizumab for locally advanced esophageal squamous cell carcinoma (ESCC) has not been firmly established. This study compared the efficacy o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Shu, Xu, Guanghui, Li, Mengbin, Zheng, Jiyang, Wang, Yuhao, Feng, Xiangying, Luo, Jialin, Wang, Shibo, Liu, Huan, Duan, Weiming, Zhang, Hushan, Huang, Depei, Zhao, Feilong, Nie, Yongzhan, Yang, Jianjun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10038194/ https://www.ncbi.nlm.nih.gov/pubmed/36969032 http://dx.doi.org/10.3389/fonc.2023.1139990

Ejemplares similares

Efficacy and safety of camrelizumab in combination with neoadjuvant chemotherapy for ESCC and its impact on esophagectomy
por: Qiao, Yujin, et al.
Publicado: (2022)

Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial: A randomized clinical trial of neoadjuvant therapy for ESCC
por: Li, Yong, et al.
Publicado: (2023)

Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab compared with chemotherapy alone and chemoradiotherapy for locally advanced esophageal squamous cell cancer
por: Zhang, Baihua, et al.
Publicado: (2023)

Landscape of RB1 alterations in 22,432 Chinese solid tumor patients
por: Xu, Guanghui, et al.
Publicado: (2022)

Neoadjuvant Camrelizumab Plus Platinum-Based Chemotherapy vs Chemotherapy Alone for Chinese Patients With Resectable Stage IIIA or IIIB (T3N2) Non–Small Cell Lung Cancer: The TD-FOREKNOW Randomized Clinical Trial
por: Lei, Jie, et al.
Publicado: (2023)

Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study
por: Yang, Peng, et al.
Publicado: (2021)

Neoadjuvant camrelizumab plus chemotherapy in locally advanced oesophageal squamous cell carcinoma: a retrospective cohort study
por: Zhou, Rui-Qin, et al.
Publicado: (2023)

Crosstalk between the gut microbiome and clinical response in locally advanced thoracic esophageal squamous cell carcinoma during neoadjuvant camrelizumab and chemotherapy
por: Xu, Liwei, et al.
Publicado: (2022)

Neoadjuvant PD-1 blockade combined with chemotherapy is not superior to neoadjuvant chemotherapy alone in resectable locally advanced esophageal carcinoma
por: Cheng, Daoan, et al.
Publicado: (2023)

An Assessment of Combination of the Camrelizumab With Chemotherapy in Metastatic Biliary Tract Cancers
por: Yu, Yi, et al.
Publicado: (2021)

Clinical Complete Remission of An Advanced Gastric Adenocarcinoma After Camrelizumab Plus Chemotherapy Followed by Camrelizumab Plus Capecitabine: A Case Report
por: Lin, Jieheng, et al.
Publicado: (2021)

Neoadjuvant camrelizumab and chemotherapy in patients with resectable stage IIIA squamous non-small-cell lung cancer: Clinical experience of three cases
por: Li, Xin, et al.
Publicado: (2022)

Cost-Utility Analysis of Camrelizumab Plus Chemotherapy Versus Chemotherapy Alone as a First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer in China
por: Chen, Ting, et al.
Publicado: (2022)

Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma
por: Liu, Jun, et al.
Publicado: (2022)

The Safety and Efficacy of Neoadjuvant Camrelizumab Plus Chemotherapy in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Retrospective Study
por: Yin, Guo-Qiang, et al.
Publicado: (2022)

The Sensitivity Prediction of Neoadjuvant Chemotherapy for Gastric Cancer
por: Sun, Juan, et al.
Publicado: (2021)

Intensive cycles of neoadjuvant camrelizumab combined with chemotherapy in locally advanced esophageal squamous cell carcinoma: a single-arm, phase II trial
por: Yang, Guozhen, et al.
Publicado: (2023)

Cost-effectiveness of camrelizumab plus chemotherapy vs. chemotherapy in the first-line treatment of non-squamous NSCLC: Evidence from China
por: Dai, Hongbin, et al.
Publicado: (2023)

Correction: Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma
Publicado: (2022)

Efficacy and safety of camrelizumab plus chemotherapy versus chemotherapy alone in patients with untreated, HER2-negative, unresectable locally advanced, or metastatic gastric cancer or gastroesophageal junction cancer: a retrospective comparative cohort study
por: Xiang, Jinyu, et al.
Publicado: (2022)

The prospect of immunotherapy combined with chemotherapy in patients with advanced non-small cell lung cancer: a narrative review
por: Ning, Xiangu, et al.
Publicado: (2021)

Development and validation of a prognostic nomogram for gastrointestinal stromal tumors in the postimatinib era: A study based on the SEER database and a Chinese cohort
por: Wang, Shu, et al.
Publicado: (2023)

Prognosis and Progression of ESCC Patients with Perineural Invasion
por: Xu, Guanghui, et al.
Publicado: (2017)

Arsenic nano complex induced degradation of YAP sensitized ESCC cancer cells to radiation and chemotherapy
por: Zhou, Wei, et al.
Publicado: (2020)

Neoadjuvant apatinib plus tegafur/gimeracil/oteracil potassium (S‑1)/oxaliplatin chemotherapy vs. chemotherapy alone in patients with locally advanced gastric carcinoma
por: Wang, Zhenfeng, et al.
Publicado: (2022)

Propensity score regression analysis of oesophageal adenocarcinoma treatment with surgery alone or neoadjuvant chemotherapy
por: Powell, A. G. M. T., et al.
Publicado: (2020)

A small-scale, exploratory real-world study of nab-paclitaxel combined with oxaliplatin and tegafur in the perioperative treatment of advanced gastric cancer: a study protocol for a real-world clinical trial
por: Zheng, Jiyang, et al.
Publicado: (2023)

Neoadjuvant chemoradiotherapy with camrelizumab in patients with locally advanced esophageal squamous cell carcinoma
por: Chen, Fei, et al.
Publicado: (2022)

Comparison of neoadjuvant immunotherapy plus chemotherapy versus chemotherapy alone for patients with locally advanced esophageal squamous cell carcinoma: A propensity score matching
por: Jing, Shao-Wu, et al.
Publicado: (2022)

Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer
por: Lin, Zhenyu, et al.
Publicado: (2021)

Correction to: Arsenic nano complex induced degradation of YAP sensitized ESCC cancer cells to radiation and chemotherapy
por: Zhou, Wei, et al.
Publicado: (2021)

Efficacy and safety of camrelizumab (a PD-1 inhibitor) combined with chemotherapy as a neoadjuvant regimen in patients with locally advanced non-small cell lung cancer
por: Hou, Xinlei, et al.
Publicado: (2022)

Neoadjuvant camrelizumab plus chemotherapy for locally advanced cervical cancer (NACI Study): a study protocol of a prospective, single-arm, phase II trial
por: Chen, Jing, et al.
Publicado: (2023)

Neoadjuvant PD‐1 inhibitor combines with chemotherapy versus neoadjuvant chemotherapy in resectable squamous cell carcinoma of the lung
por: Feng, Yuan, et al.
Publicado: (2021)

Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA
por: Tsuboi, Masahiro, et al.
Publicado: (2021)

Impact of neoadjuvant chemotherapy with PELF-protocoll versus surgery alone in the treatment of advanced gastric carcinoma
por: Ruf, Catharina, et al.
Publicado: (2014)

Author response to: Neoadjuvant chemoradiotherapy or chemotherapy alone for oesophageal cancer: population-based cohort study
por: Kamarajah, S K, et al.
Publicado: (2021)

Identification of patients with locally advanced rectal cancer eligible for neoadjuvant chemotherapy alone: Results of a retrospective study
por: Han, Yi‐min, et al.
Publicado: (2023)

Clinical effects of Apatinib combined with DOS neoadjuvant chemotherapy regimen in neoadjuvant chemotherapy for LAGC
por: Zhou, Peng-zhe, et al.
Publicado: (2021)

Delta-radiomics based on CT predicts pathologic complete response in ESCC treated with neoadjuvant immunochemotherapy and surgery
por: Li, Kaiyuan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_iftm3fkfplrkl69de8921p7ejs